Glypican‐3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment

E-ISSN： 1098-1128|38|2|741-767

ISSN： 0198-6325

Source： MEDICINAL RESEARCH REVIEWS, Vol.38, Iss.2, 2018-03, pp. : 741-767

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Health disparities in diagnosis and treatment of hepatocellular carcinoma

CLINICAL LIVER DISEASE (ELECTRONIC), Vol. 4, Iss. 6, 2014-12 ,pp. : 143-145

John Wiley & Sons Inc

Access to resources Recommend Favorite

Criteria for liver transplantation in hepatocellular carcinoma

CLINICAL LIVER DISEASE (ELECTRONIC), Vol. 6, Iss. 4, 2015-10 ,pp. : 100-102

John Wiley & Sons Inc

Access to resources Recommend Favorite

Aptamers against Cells Overexpressing Glypican 3 from Expanded Genetic Systems Combined with Cell Engineering and Laboratory Evolution

ANGEWANDTE CHEMIE INTERNATIONAL EDITION, Vol. 55, Iss. 40, 2016-09 ,pp. : 12372-12375

John Wiley & Sons Inc

Access to resources Recommend Favorite

Aptamers against Cells Overexpressing Glypican 3 from Expanded Genetic Systems Combined with Cell Engineering and Laboratory Evolution

ANGEWANDTE CHEMIE, Vol. 128, Iss. 40, 2016-09 ,pp. : 12560-12563

John Wiley & Sons Inc

Access to resources Recommend Favorite

Intra‐arterial locoregional therapy in the management of hepatocellular carcinoma

CLINICAL LIVER DISEASE (ELECTRONIC), Vol. 11, Iss. 1, 2018-01 ,pp. : 6-10

John Wiley & Sons Inc

Access to resources Recommend Favorite